Vessix Vascular, Inc. to Present V2 Renal Denervation System(TM) for Hypertension at LINC 2012

LAGUNA HILLS, Calif., Jan. 18, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that the first public presentation of its new percutaneous V2 Renal Denervation System for the treatment of medication-resistant hypertension will be made at LINC 2012 in Leipzig, Germany on Thursday, January 26, 2012.

Renal denervation is a new percutaneous catheter-based technique for the treatment of medication resistant or uncontrolled hypertension. The new V2 Renal Denervation System is designed to be faster, easier to deploy and less invasive for the patient than the alternatives available today in the market.

The presentation, titled “Radiofrequency balloon-mediated renal denervation: The V2 Catheter by Vessix Vascular,” will be made by Prof. med. Horst Sievert during a session for new emerging technologies for renal denervation chaired by Krishna Rocha-Singh, M.D.

Dr. Sievert, a globally recognized interventional cardiologist based in Frankfurt, Germany, is a key opinion leader in the field of renal denervation.

Vessix’s new device, the V2 System for the treatment of medication-resistant hypertension, is an over-the-wire, balloon catheter with electrodes and thermistors mounted on the exterior of the balloon to facilitate the delivery of RF energy to the nerves surrounding the renal artery. Vessix will begin its first-in-man clinical study next month.

Key benefits of the Vessix approach to renal denervation include:

• Therapy is delivered via a balloon catheter that is quite familiar to interventional cardiologists and other physicians, thereby increasing the usability and safety profile of the device.
• Ability to deliver RF treatment in as little as thirty (30) seconds per artery, which is significantly faster than the only other competitively marketed renal denervation system that takes 20-30 minutes to deliver treatment to each renal artery.
• Rapid RF treatment time greatly increases the efficiency of the procedure, significantly reduces discomfort for the patient and provides the benefits of lower exposure to radiation, lower amount of contrast dye and, therefore, lower renal toxicity to the patient.

About Vessix Vascular, Inc. Vessix, initially founded in 2003 as Minnow Medical, Inc. is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company’s initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries. For more information on Vessix Vascular, please visit the Company’s website at www.vessixvascular.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at matt@allencaron.com.

SOURCE Vessix Vascular, Inc.